EcoDrugPlus

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSACLG00000012125
Gene Symbol: HTR1B
2 Cross references
178 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSACLG00000017966
Gene Symbol: HTR1B
2 Cross references
180 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSACLG00000020006
Gene Symbol: HTR1F
2 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSACLG00000014856
Gene Symbol: HTR2A
3 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a-Like

Ensembl ID : ENSACLG00000022071
Gene Symbol: LOC113019096
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSACLG00000026741
Gene Symbol: HTR2B
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSACLG00000021894
Gene Symbol: HTR3A
1 Cross references
205 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSACLG00000021873
Gene Symbol: HTR3B
3 Cross references
175 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSACLG00000018039
Gene Symbol: HTR4
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSACLG00000027619
Gene Symbol: HTR5A
3 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine Receptor 6

Ensembl ID : ENSACLG00000013322
Gene Symbol: HTR6
1 Cross references
115 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSACLG00000001146
Gene Symbol: HTR7
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).